Edwards Lifesciences Corporation
EW
$85.28
-$1.90-2.18%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.57B | 1.55B | 1.53B | 1.41B | 1.39B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.57B | 1.55B | 1.53B | 1.41B | 1.39B |
| Cost of Revenue | 343.00M | 345.20M | 344.40M | 301.60M | 292.20M |
| Gross Profit | 1.23B | 1.21B | 1.19B | 1.11B | 1.09B |
| SG&A Expenses | 601.20M | 514.60M | 502.00M | 465.70M | 491.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -14.30M | -12.50M | -21.30M | -19.10M | -22.70M |
| Total Operating Expenses | 1.20B | 1.13B | 1.10B | 1.00B | 1.03B |
| Operating Income | 372.00M | 425.10M | 430.90M | 409.90M | 353.90M |
| Income Before Tax | 90.40M | 348.40M | 400.20M | 433.90M | 390.10M |
| Income Tax Expenses | 26.20M | 56.10M | 64.30M | 70.30M | 45.10M |
| Earnings from Continuing Operations | 64.20M | 292.30M | 335.90M | 363.60M | 345.00M |
| Earnings from Discontinued Operations | 27.00M | -2.00M | -4.40M | -7.20M | 39.30M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 800.00K | 1.70M | 1.60M | 1.30M |
| Net Income | 91.20M | 291.10M | 333.20M | 358.00M | 385.60M |
| EBIT | 372.00M | 425.10M | 430.90M | 409.90M | 353.90M |
| EBITDA | 414.70M | 464.30M | 469.00M | 446.50M | 396.60M |
| EPS Basic | 0.16 | 0.50 | 0.57 | 0.61 | 0.65 |
| Normalized Basic EPS | 0.50 | 0.48 | 0.43 | 0.46 | 0.40 |
| EPS Diluted | 0.15 | 0.50 | 0.56 | 0.61 | 0.65 |
| Normalized Diluted EPS | 0.50 | 0.48 | 0.43 | 0.46 | 0.40 |
| Average Basic Shares Outstanding | 580.40M | 584.70M | 587.00M | 586.90M | 589.80M |
| Average Diluted Shares Outstanding | 581.80M | 585.70M | 587.90M | 587.80M | 590.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |